MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally...

|About: MAP Pharmaceuticals, Inc. (MAPP)|By:, SA News Editor

MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally inhaled drug for the potential treatment of acute migraine, has been accepted for filing by the FDA. The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26 action letter and has set a goal date of April 15, 2013 under the prescription drug user fee act.